Investors

News Releases

Keyword Search

Date Title  
Toggle Summary Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
-Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET - MISSISSAUGA, Ontario , March 6, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its 2017 fourth quarter and full-year financial results on Tuesday, March
Toggle Summary Aralez to Present at the 2018 BIO CEO and Investor Conference
MISSISSAUGA, Ontario , Jan. 30, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the 2018 BIO CEO and Investor Conference to be held February 12-13, 2018 in New York .
Toggle Summary Aralez Announces Departure of Chief Financial Officer
MISSISSAUGA, Ontario , Nov. 30, 2017 /PRNewswire/ --   Aralez Pharmaceuticals Inc.   (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that Scott J. Charles , Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately.
Toggle Summary Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter
  -3Q 2017 Net Revenues of $24.3 Million ; Year-to-Date 2017 Net Revenues of $77.9 Million -   -Implements Fiscal Improvements designed to Deliver Profitability, Support Growth & Extend Cash Runway- -Provides Updated 2017 Full-Year Guidance and Preliminary 2018 Full-Year Outlook- MISSISSAUGA,
Toggle Summary Aralez To Report Third Quarter 2017 Financial Results On November 9, 2017
-Executive Management to Host Conference Call on November 9, 2017 at 8:30 a.m. ET - MISSISSAUGA, Ontario , Oct. 25, 2017 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017
Toggle Summary Aralez Reports Second Quarter 2017 Financial Results
-2Q 2017 Net Revenues of $27.6 Million, a $15.0 Million Increase Compared to 2Q 2016- -First Half 2017 Net Revenues of $53.6 Million, a $33.0 Million Increase Compared to First Half 2016- MISSISSAUGA, Ontario , Aug. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc.
Toggle Summary Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017
-Executive Management to Host Conference Call on August 9, 2017 at 9:00 a.m. ET -  MISSISSAUGA, Ontario , July 24, 2017 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its second quarter 2017 financial results on Wednesday, August 9, 2017 ,
Toggle Summary Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents
 -Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy's Laboratories , Mylan, and Lupin-  MISSISSAUGA, Ontario , June 27, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that the United States District
Toggle Summary Aralez Announces National U.S. Commercial Launch Of Zontivity
-Zontivity® is the Only Approved Protease-Activated Receptor-1 (PAR-1) Inhibitor, a Receptor for Thrombin on the Platelet Considered to be a Potent Platelet Activator- -75 Aralez Sales Representatives Now Targeting 12,000 Cardiologists, Primary Care Physicians and Vascular Surgeons- MISSISSAUGA,
Toggle Summary Aralez Announces Board Member Resignation

Data Provided by Refinitiv. Minimum 15 minutes delayed.